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Three mouse strains as well as wt and 7 ts mutants of 
herpes simplex virus (HSV) type 2 (strain HG52) have 
been used to investigate latency. The mice were inocu­
lated in the right rear footpad. Virus reactivation fol­
lowing explanation and culture of the dorsal root gan­
glia and the footpad was scored. The results show that: 
(1) HSV-2 can be maintained in the mouse footpad in a 
state indistinguishable from latency; 2) virus gene func­
tions necessary for latency can be identified by the use 
ofts mutants; and (3) mouse strains differ in their ability 
to support latent infection. An infectious center assay 
was used to quantitate virus reactivation from disso­
ciated dorsal root ganglia. HSV -1 strain 17 wt spread 
after inoculation at doses of::::: 5.0 x 105 plaque-forming 
units (pfu), producing latency also in contralateral gan­
glia but with lower efficiency. 
The great majority of viruses invade and productively infect 
the natural host's susceptible cells; this triggers an immune 
response and as a result the virus is usually eliminated from 
the host's body. Following recovery the individual is then 
usually protected against a further infection by the same or an 
antigenically similar virus. At all times, the virus population is 
generated and maintained by successive cycles of productive 
infection. The viral genomes are exposed to immediate selection 
at every infectious cycle; only progeny that for one reason or 
another survive these multiple internal and external selective 
pressures contribute to the composition of the next generation's 
gene pool. Frequent genetic changes of the virus population 
can result-an extreme illustration is provided by the con­
stantly changing influenza A virus. A large population of po­
tential hosts is needed for such virus to be maintained endemic 
in the region; moreover, the population of viral genomes form­
ing the gene pool varies with availability of susceptible individ­
uals. 
However, the herpes viruses have evolved an additional strat­
egy: the facility to produce latency which stabilizes the com­
position of the viral gene pool over longer periods of time. This 
strategy is accomplished by the virus succeeding in establishing 
a state of latency in privileged host cells, in the case of HSV 
neurons, from which it retains the capability of reactivating 
periodically to produce repeated productive localized infections 
which may serve as sources of virus and cause primary infec­
tions in other individuals. Opportunity for selectively imposed 
genetic change occurs at every round of viral genome replica­
tion. When the virus is latent, this opportunity does not recur 
every few hours or days as is the case during normal infectious 
cycles, but only at infrequent intervals (months or years) when 
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reactivation occurs. Thus herpes viruses have retained all the 
potential advantages of the productive infectious cycle, with 
the added boon that progeny of the same genome are repeatedly 
exposed to selection over many years. The population of viral 
genomes forming t.he gene pool is at all times large and stable 
and continues to evolve with the host. 
The term latency as used here implies the ability of the viral 
genome to infect and remain essentially dormant and unex­
posed to selection in certain host cells-it remains "frozen" for 
very prolonged periods of time. At all times latent genom($ 
retain the potential to reactivate, producing fully viable progeny 
virus particles that can infect other host cells and hence also 
new hosts. A latent virus genome survives in a privileged site 
and is not detected by, or exposed to, the host's immune 
defenses. In the case of HSV, it has become widely accepted 
that the viral genome, following primary infection at the pe­
riphery, establishes latency in nervous tissue, particularly in 
neuronal cell bodies of the sensory ganglia anatomically related 
to the affected sites [1]. However, evidence is beginning to 
accumulate that there may be additional cell types in which 
HSV can establish latency. 
Humans are the only natural host of herpes simplex virus 
(HSV), type 1 and type 2. HSV-1, often referred to as facial 
herpes, has been shown to be able to become latent in the 
trigeminal [2], superior cervical, and vagus ganglia [3]. On 
reactivation, HSV -1 may initiate lesions on the lips, mouth, 
eye, or less commonly, on other sites in the dermatome inner­
vated by the respective sensory ganglion, and infectious virus 
can be isolated from these overt lesions. At times, following 
reactivation, HSV is shed in the absence of detectable lesions 
[4]. HSV-1 has also, with increasing frequency, been isolated 
from the genital regions. HSV -2 has a predilection for infecting 
the genital regions of men and women and is frequently referred 
to as herpes genitalis. 
Herpes virus infecting the genital regions has been shown to 
go latent in the sacral ganglia [5] and there is, in addition, one 
recent report of successful reactivation from explanted utero­
sacral ligaments in which occasional parasympathetic ganglia 
could be demonstrated [6]. Reactivation usually leads to lesions 
on the cervix, external genitalia, the anal region, and the 
buttocks. 
Latency is postulated to become established by virus genomes 
travelling up the axons of sensory neurons innervating the 
region of the neuronal cell body in the ganglion and entering a 
dormant state there. The molecular biology of latency has still 
to be elucidated. Occasionally in response to a variety of stimuli, 
either external or initiating in the host's body, the latent 
genomes are caused to reactivate with the production of infec­
tious virus. Here again the molecular events remain obscure. 
The progeny viral genomes are thought to travel via the axo­
plasm by axonal transport to the periphery-whether as sub­
viral or fully formed virus particles is not established-and are 
there able to cause productive infection and local lesions. 
Whether a neuron in which reactivation occurs is or is not 
destroyed in the process is still controversial. Normally, cells 
that are productively infected are destroyed as a consequence 
of producing and releasing virus progeny. 
Many attempts to isolate latent herpes virus established that 
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the virus could be reactivated only by explantation of ganglionic 
tissue and then only provided that the tissue was explanted 
within a few hours after death [7]. It was not possible to 
reactivate virus by explanting tissue from the peripheral sites 
(e.g., skin) , in which recurrence normally took place, unless an 
overt lesion was present [8]. In an extensive study [3,9,10], a 
variety of ganglia were explanted within 24 h of death from 
many individuals who had died of trauma. Reactivated virus 
was subjected to restriction endonuclease analysis and the 
findings established that (a) the HSV genome reactivated from 
every individual could be distinguished from that obtained from 
any other, (b) where several different isolations were made 
from explants of the same ganglion, they produced indistin­
guishable virus genomes, (c) virus isolates from different gan­
glia of the same individual always possessed indistinguishable 
genomes, and (d) all isolates from these sensory ganglia were 
HSV-1. These findings strongly suggest that HSV, at the time 
of its primary infection, had spread and established latency in 
different neurons of one or more ganglia. Latency has subse­
quently been maintained without the type of evolutionarily 
acquired small changes taking place that would be expected if 
the viral genomes were continuously replicating throughout the 
latent period [11]. Following the initial establishment of HSV 
latency, it appears to become much more difficult for a subse­
quently infecting HSV strain to establish latency, even though 
many episodes of reinfection must occur during the lifetime of 
that individual. However, patients infected with both types of 
HSV are not uncommon, and individuals presenting with re­
current HSV-1 in the facial regions and HSV-2 in the genital 
regions have been reported. In most of these cases, rigorous 
proof that the virus was truly latent in the sensory ganglia is 
not available but this can be assumed. 
Humans are the natural host for HSV, but laboratory animals 
can be infected and provide several model systems for the study 
of latency [1, 7]. Two model systems particularly relevant to 
our study use the guinea pig footpad and the mouse ear. Scriba 
studied infection of the guinea pig and reported that the virus 
produces latency in the dorsal root ganglia (DRG) following 
injection into the footpad (FP) of the hind limb, but infectious 
virus could subsequently be isolated at most times from the site 
of inoculation [12-14]. Several different mouse models have 
been established and in all of them, latent virus can be reacti­
vated by explantation of the relevant nervous tissue. In recent 
years, Hill and colleagues have extensively studied a mouse ear 
model in which viral reactivation occurs spontaneously at low 
frequency leading to microscopic lesions in the skin [15]. The 
frequency of reactivation can be increased following stimulation 
of the ear skin [16-] 8]. Extensive earlier attempts to reactivate 
virus succeeded only in reactivating HSV from sensory ganglia, 
brain tissue, and the adrenal gland of the mouse [7]. 
Early collaborative experiments between Stevens' and Su­
bak-Sharpe's groups provided the first qualitative evidence that 
specific HSV -1 ts mutants affect latency [19,20]. Our labortory 
has now undertaken a more extensive genetic study of HSV-2 
latency using 7 ts mutants from different complementation 
groups [21-23J and 3 different strains of mice. The aims were 
threefold: 
1. To establish whether genetically distinct mouse strains 
infected identically exhibit latency at different frequen­
cies. 
2. To reinvestigate whether virus can be reactivated only 
from the DRG or also from explanted tissue from the site 
of inoculation (FP) which is not known to contain neu­
ronal cell bodies. 
3. To identify HSV -2 ts mutations that alter the ability of 
the virus to establish latency in the DRG of the mouse. 
Our results demonstrate: 
1. Mouse host strain differences; 
2. HSV -2 ts mutant related effects; 
3. Maintenance of HSV -2 in the mouse footpad in a state 
indistinguishable by present criteria from latency. 
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The work extends to 3 mouse strains, our recent findings 
using thirteen HSV -2 ts mutants in the Biozzi strain [24]. 
MATERIALS AND METHODS 
These are as described previously [24,25]. Mice of 3 strains bred on 
site were: Pirbright (a randomly mated closed colony), Biozzi (high 
antibody responder), and A. 
We examined HSV-2 strain HG52 wt and 7 derived ts mutants from 
different complementation groups [21-23]. Aliquots (0.025 m!) of virus 
suspended in Dulbecco's phosphate-buffered saline supplemented with 
10% calf serum were injected into the right rear FP of 3- to 4-week-old 
mice of either sex. The mouse core body temperature (38.5°C) conforms 
to nonpermissive temperature for the 7 ts mutants; however, when the 
mice are active, their FPs may be somewhat below the core body 
temperature, but when close packed and asleep in the nest, the FPs too 
will be at or near the core temperature. Mice were kept for at least 3 
months following infection. None of the mice inoculated with HSV-2 
strain HG52 wi or the ts mutants died as a consequence, though some 
developed temporary swelling and reddening of the injected FP lasting 
2-3 days. Altogether 4 mice, all inoculated with wt, developed paralysis. 
Three months later, the mice were killed and tested for latent virus by 
immediately explanting the left and right DRG and left and right FP. 
Ganglia and FPs were placed individually into microtiter plate wells in 
medium consisting of Eagle's/50% fetal calf (EFC50) and incubated at 
31°C for up to 60 days with screening of the supernatant daily (FP) or 
on alternate days (DRG) for infectious virus by plating onto monolayers 
of BHK21/C13 cells. To be scored as negative, DRG or FP had to have 
been incubated for a minimum of 21 days. All the isolates were checked 
for temperature sensitivity. Invariably, ts mutants retained their ts 
phenotype while wt virus remained non-ts. 
FP tissue was explanted by first cleaning and washing both hind feet 
with absolute alcohol, then a sliver of FP was excised from each side 
with separate sterile instruments for each and dipped for 20 s into 
absolute alcohol. After washing the explanted tissue twice in EFC50, 
fragments were placed into separate microtiter wells, epidermal side 
up, and sufficient EFC50 added to cover the epidermal surface. Sensory 
ganglia (2 thoracic, the 6 lumbar, and the 1st sacral.), were dissected 
out, washed separately, and placed into individual microtiter plate wells 
containing EFC50. Incubation proceeded at 31°C. 
For dissociation of DRG, ganglia from the left and right sides were 
removed from pairs of mice and placed into 2 pools, one from the left 
and one from the right. The pooled ganglia were teased with fine 
forceps and then digested in 2 ml of 2% collagenase by incubation at 
37°C for 2 h. Subsequently, the ganglia were dissociated into a single 
cell suspension by trituration through a plastic (Eppendorf) tip, cen· 
trifuged at 500 g for 10 min and resuspended in 15 ml fresh medium 
containing 5% human serum. Each cell suspension was then distributed 
in 3-ml volumes to 5 30-mm plastic Petri dishes (Nunc) containing a 
semiconfluent monolayer of BHK21/C13 cells. The dishes were then 
incubated at 31°C for 10 days, fixed and stained with Giemsa, and the 
number of infectious centers enumerated by scoring plaques. 
On Reveral occasions, DRGs and FPs were homogenized immediately 
following dissection and test-plated, but no infectious virus was ever 
detected. 
RESULTS 
Table I lists the recovery of 7 ts mutants and the wt of HSV-
2 HG52 from DRG and FP of 3 mouse strains. At no time was 
virus recovered either from the un inoculated left rear FP or 
from the contralateral DRG. The infecting dose used lay be­
tween 1.2-17 X 105 pfu except for ts4 where it was 50 X 105 pfu. 
At the time of inoculation, the inoculum was simultaneously 
titrated on BHK21 C13 cells. 
A number of points emerge: 
1. Wt and ts mutant virus was recovered, not only from the 
DRG, but also from the FP tissue of all 3 mouse strains. 
2. In general, ts mutants reactivated from the DRG less 
frequently than the wt virus. This trend is also noticeable 
for FP. 
3. There is a (not always consistent) strain-dependent dif­
ference in the number of mice from which latent virus 
reactivates: the order is A > Biozzi > Pirbright. 
4. With respect to latency, the ts mutants can be separated 
into 4 classes: Class 1 behaves more or less like wt and 
can be recovered both from the DRG and from the FP 
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TABLE I. Recovery of HS V-2 HG52 wt or ts virus from dorsal root ganglia (DRG) and footpad (FP) of 3 different strains of mice 
---�--. 
Mouse strain Total 
Virus Dose Pirbright Biozzi A (pfu x 105) DRG % FP % 
DRG FP DRG FP DRG FP 
Is2 17.0 O/W 1/11 b 8/17 1/16 8/9 2/9 16/40 40.0 4/36 11.1 
ts3 1.2 0/14 1/6 0/16 5/15 0/24 5/15 0/54 0 11/36 30.5 
ts4 50.0 2/15 0/15 12/14 1/14 6/15 8/14 20/44 45.5 9/4:� 20.9 
Is5 17.0 0/13 0/13 0/12 0/12 0/11 0/11 0/36 0 0/36 0 
tsll 4.2 0/12 0/12 1/12 0/12 2/13 0/12 3/37 8.1 0/36 0 
t812 5.0 3/14 1/12 0/14 1/14 4/13 1/11 7/41 17.1 3/37 8.1 
tsl3 6.0 2/11 1/9 2/14 0/14 1/11 2/11 5/36 13.9 3/34 8.8 
Total ts 7/93 4/78 23/99 8/97 21/96 18/83 51/288 29/258 
% Is positive 7.5 5.1 23.2 8.2 21.9 21.7 17.7 11.2 
wI HG52 1.0 9/15 3/22 11/13 1/14 5/5' 3/5' 
% wt positive 60 13.6 84.6 7.1 100 60 ---- ---
o Number of positive/total mice tested. 
b Despite precautions. the explanted FP tissue became contaminated in a number of cases and was discarded. 
, 1.0 x 106 pfu/mouse. 
(ts2, ts4, ts12, and ts13). Class 2 is not recovered from 
either DRG or FP (ts5). Class 3 is recovered only from the 
DRG and not from the FP (ts11). Class 4 is recovered only 
from the FP but not from the DRG (ts3). 
The number of mice of the 3 strains tested is just over 100 
each and the virus has been tested only at a single dose to date. 
Thus when these investigations are extended, the class sepa­
ration of the mutants' behavior may become less clearcut and 
"only rarely" may have to be substituted for "not" in the 
definitions. Nevertheless, we consider that our data are suffi­
cient to justify the above assignment of our 7 mutants to the 4 
classes. More extensive data may reveal more subtle ts mutant­
mouse strain interactions, as possibly already suggested by ls2. 
Table I shows that wt HG52 is readily recovered from latency 
in the DRG of all 3 strains of mice: 85% of the Biozzi strain 
and 60% of the Pirbright strain yielded virus after an initial 
inoculum of 1.0 X 10" pfu (injected with 1.0 x 10" pfu of wt 
virus, 6/6 of Biozzi and 6/6 of Pirbright strain mice yielded 
virus). Although the wt can be assumed to replicate readily at 
the peripheral and core temperatures of the mice, virus is much 
less often recovered from the FP than from the D RG of these 
3 strains of mice. 
Mutant ts2 behaved somewhat similarly to wt virus, but did 
not reactivate from the DRG of Pirbright mice (14 mice). 
Mutant ts3 was at no time recovered from the DRG but readily 
from the FP of all 3 strains of mice. Mutant ts4 behaved 
somewhat similarly to wt both for DRG and FP. This virus 
reactivated with very high efficiency from the DRG of Biozzi 
mice (12/14), but they had been injected at the high infectious 
dose of 5 .0 X 106 pfu/mouse. Mutant ts5 has never been 
recovered from DRG or FP of the 3 mouse strains. Mutant ts11 
has been recovered 3 times from DRG, (l/12 in Biozzi, 2/13 in 
A), but never from the FP. Mutants ts12 and ts13 behaved 
somewhat similarly to wt. 
If we compare the combined results from the 6 reactivation 
positive mutants (ts2, 3, 4, 11, 12, and 13) with the wt, we find 
for the DRG 7/80 vs 9/15 (Pirbright); 23/87 vs 11/13 (Biozzi); 
21/85 vs 5/5 (A) , and for the FP 4/65 vs 3/22 (Pirbright); 8/85 
vs 1/14 (Biozzi); and 18/72 vs 3/5 (A). Thus, on average, the ts 
mutants are much less often recovered from the DRG than are 
the wt, but are recovered with comparable frequency from the 
FP. These differences obtain despite much higher doses of ts 
mutant virus (in the cases of ts2, ts4, and ts5) than wt virus. 
What is the evidence of virus latency in the FP, as opposed 
to persistent local infection at the site of inoculation? 
First, on several occasions FPs have been homogenized im­
mediately following dissection and screened for virus-always 
with negative results. 
Second, we have data for 37 mice (4 of these had been 
inoculated with HG52 wt and 33 with intertypic HSV-l/HSV-
2 recombinants which grow normally at 31 'C or 38.5'C) where 
a FP was cut in half and one piece immediately homogenized 
while the other was explanted and incubated as usual. Virus 
could in no case be recovered from the homogenized half, but 
reactivation took place after several days in each of the 37 
explanted half FPs. 
Third, the time of first virus recovery from FP indicates 
latency (Table II). The earliest observation of reactivation from 
the DRG has been on day 8 after explantation, while in some 
cases virus was not detected in the supernatant before day 26. 
The respective FP data showed the earliest time of virus 
detection to be day 8 and the latest day 44 following explanta­
tion. Thus the FP mode of reactivation closely reflects reacti­
vation from latency in DRG, but does not conform with the 
rapid recovery expected were the FP persistently infected. It is 
worth pointing out that the time of reactivation from the 
explants does not appear to vary among mouse strains. 
We have obtained some evidence concerning the effect of 
varying the virus dosage at the time of infection on the ability 
to reactivate latent HSV-1 strain 17 wt virus from the DRG of 
Biozzi mice. The results in Table III show the average number 
of infectious centers per mouse obtained from plating out 
dissociated ganglia. The number of foci (infectious centers) 
recoverable from dissociated DRG increases with the dose 
initially used to infect them, ranging from an average of 4 foci 
per mouse at a dose of 3.0 X 10:3 pfu to 85 foci per mouse at 1.0 
X 107 pfu. Following infection with high doses, virus has also 
been reactivated from the contralateral ganglia but at much 
lower efficiency (Table III). 
DISCUSSION 
Over recent years, opinion has hardened that HSV latency 
is due to the viral genome entering the still undefined dormant 
state in the neuronal cell body in sensory ganglia. The most 
direct. evidence is t.hat HSV antigens first appear in neurons 
when DRG of latently infected mice are undergoing reactiva­
tion in vitro [25-27]. In humans, with one possible exception 
[28], HSV has only been reactivated in culture from the latent 
state in tissue in which neuronal cell bodies are known to be 
present. It has, however, been known and accepted for many 
years now-largely due to the work of Scriba-that HSV -2 can 
be recovered from what appeared to be a persistent infection 
at the site of inoculation in the FP of the guinea pig. Unlike 
the situation we have found in the mouse, infectious virus could 
be demonstrated frequently in the guinea pig FP soon after 
explantation [12- 14]. HSV-2 has been isolated also by another 
group of investigators from the guinea pig FP [29], and HSV-1 
from the ear skin (the site of inoculation) in 8% of latently 
infected mice, in the absence of observable lesions [30]. In 
general, the view that the neuronal cell body is where virus 
establishes latency has become so entrenched that the possi-
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TABLE II. Time of reactivation of virus from dorsal root ganglia (DRG) and footpad (FP) in different strains of mice 
Mouse strain 
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(14) 
ts13 14-18 20 
(16) 














a Figure in parenthesis indicates the mean. 
b 1.0 X 10' pfu/mouse. 
, 1.0 X 106 pfu/mouse. 
TABLE III. Infectious center assay of cells from dissociated Biozzi 
ganglia latently infected with HSV-J wt 
Right DRG (side of infection) 
Left DRG 
Dose of virs inoculated (pfu) 









a Number of foci of cytopathic effects (cpe) scored on an indicator 
layer of BHK21 C13 cells, each number is the average of 4 mice. 
bility that HSV might achieve latency in other cell types has 
largely been discounted. 
Three different models of virus latency have been proposed. 
Basing his own seminal findings on much earlier but less critical 
work, Stevens developed the classical hypothesis of latency 
[7]: this proposes that the viral genome usually remains in a 
dormant state in the neuronal cell body, but is from time to 
time induced to reactivate, producing virus particles which 
travel down the axon and then infect other cell types after 
release from nerve fibrils in the skin. A second hypothesis, the 
"skin trigger hypothesis" of Hill and Blyth [in], proposes 
latency to be a dynamic state undergoing a continuing series of 
reactivations which most of the time, however, only give rise 
to subclinical infections or abort at the periphery. Events in 
the skin itself trigger and primarily determine whether a par­
ticular episode of reactivation will succeed in producing detect­
able lesions at the periphery. A third hypothesis, "the round 
trip," was put forward by Klein [32] . This proposes that the 
reactivated virus moves from the neuronal cell body down the 
axon to infect cells at the periphery, the infected neurons in 
the process being destroyed; during amplification, the released 
virus infects neighboring fibrils of other neurons and travels 
up the axon to establish latency in their cell bodies. Thus the 
numbers of latently infected neurons are maintained in the 
individual. At present there is no final consensus of opinion, 
but it will be noted that the three hypotheses are not necessarily 
mutually exclusive. All three hypotheses involve the neuronal 
cell body as an essential component. None addresses itself to 
the problem which our investigations with HSV - 1 [:33] and 
HSV-2 [24] have raised, namely, that virus appears to be able 
to attain a state in FP tissue that is indistinguishable from 
latency. We are not aware of any anatomic evidence to suggest 
that nucleated neuronal cell bodies are likely to be present in 
mouse FP tissue, though it must be stressed that the explanted 
tissue stems from crude dissection of skin slivers and probably 
contains additional deeper dermal tissues as well. Latent HSV 
clearly cannot maintain itself by replicating because antiviral 
drugs (like acyclovir) appear to be unable to eradicate the latent 
virus [34]. We propose that there are cell types other than 
neurons which HSV can latently infect. Some of our future 
experiments will be directed toward identifying these cell types. 
Virus reactivated at different frequency from mice of 3 dif­
ferent strains that had been injected with the same virus dose 
[35,36]. This indicates that the host's genetic makeup has an 
important influence on the outcome. The effect of mouse host 
genetic makeup on HSV pathogenicity has been elegantly stud· 
ied [37,38], but at present a similar detailed study vis-a.-vis 
latency remains to be undertaken. The present data and results 
obtained by us with HSV-1 and 5 mouse strains [:36] do not 
suggest a correlation between mouse strain susceptibility to 
HSV-1 or HSV-2 and ability to act as a host for latent virus. 
It is relevant in this context that HG52 is unusual among HSV-
2 strains in being of very low pathogenicity. 
Previously the only viral gene recognized to have a function 
necessary for latency was the HSV thymidine kinase gene 
[39]. Our experiments have produced clear evidence that la­
tency is dependent on several viral gene functions, some of 
which we have pinpointed by ts mutations in different HSV-2 
genes. The generally lower rate of successful establishment of 
latency by ts mutants is notable, although it may reflect ina­
bility to replicate efficiently following injection. The real inter­
est lies in the identification of mutants like t85, ts3, and tsll. 
Ts5 seems to preclude HSV latency in either DRG or the FP 
of the mouse strains-clearly an interesting mutant to inves­
tigate in more detail and such studies are under way. Ts3 is 
also of special interest, being recovered only from explanted 
mouse FP. Tsll based on more limited data appears to have 
the opposite capability, being recovered only from the DRG. 
These two mutants imply differences in the molecular events 
involved in the process of establishing latency at the two 
different sites. It will be of considerable interest and importance 
to identify and characterize the relevant gene products and 
attempt to study their biological functions. It is of particular 
interest that mutants ts3 and ts5 are DNA-positive, while ts 11 
is DNA-negative. It should be mentioned that ts3 could not be 
recovered even after dissociation of the DRG of 4 A strain mice 
(data not shown). 
We draw attention to the results obtained with dissociated 
DRG from mice infected initially with different doses of HSV-
1. The number of foci observed in the monolayers gives an 
estimate of the number of DRG cells from which HSV reacti­
vates. These figures are likely to be underestimating the original 
number of neurons present from which HSV reactivates owing 
to loss of cells during dissociation and plating. We have shown 
that focus number increases with the initial dose and that given 
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5.0 X 105 pfu, virus spread becomes sufficiently extensive to 
allow the establishment of latency in the contralateral DRG of 
Biozzi mice. This suggests that the initial infecting dose used 
can importantly influence the outcome with respect both to 
frequency and extent of the establishment of latency. 
Finally, we believe our data on the mouse FP necessitate 
reinvestigation of the situation in humans. In particular, we 
stress the importance that explanted tissue containing both 
epidermis and dermis be incubated, constantly monitored, and 
followed for a sufficient time to ensure the validity of negative 
results. For example, our investigations in the FP of mice with 
HSV-2 would not have yielded any positive data had the 
experiments been terminated before the eighth day. In the great 
majority of cases, successful virus isolation did not occur until 
much later. 
It is a pleasure to thank Mrs. A. J. Simpson for her patience in 
typing the manuscript, and Miss M. Braidwood for technical assitance. 
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